Sign in
Not yet taking people in GermanyPhase 3

Skin prick test with allergen extracts to diagnose allergies in adults with rhinitis

Tests how well allergen skin prick tests detect allergies in adults with rhinitis.

Key facts

Who runs it
ROXALL Medizin GmbH
Where
Berlin-Charlottenburg, Dresden, and Göttingen, GermanySee the 4 sitesAlso in 1 other country, 6 sites
Registry title
International, multicenter, blinded phase III clinical trial to assess the diagnostic efficacy of the skin prick test from ROXALL (SPT-RX) with different allergen extract solutions for in vivo diagnosis of IgE mediated allergies
Status
Not yet recruiting
Phase
Phase 3
People taking part
140 people, planned
Started
1 Sept 2026
Expected to end
31 Dec 2027
Type of study
Interventional
Record updated
9 September 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with a confirmed allergy to pollen, mites or similar sources, and also people without such allergy, to test a skin prick test.

Age
18 to 65 years (registry upper limit: 64 years)
Sex
Women and men can join.
Disease stage
Runny nose or itchy eyes from allergy for at least 2 years (seasonal) or 1 year (all-year). Asthma must be well-controlled and mild-to-moderate, or absent.
Earlier treatment
Cannot have had allergen immunotherapy, anti-IgE treatment (like Omalizumab) or a checkpoint inhibitor. Cannot use drugs that interfere with skin prick tests.
Biomarker or test result
Allergic people need a positive skin prick test (wheal 3 mm or more) and specific IgE class 3 or higher (3.50 kU/L or more). Non-allergic people need a negative skin test and IgE class below 1 (below 0.35 kU/L).

Main reasons for not taking part

  • Skin problems at the test area (dermographism, atopic dermatitis, urticaria, tattoos)
  • Severe, partly controlled or uncontrolled asthma
  • Taking beta-blockers
  • Pregnancy or breastfeeding
  • High risk of anaphylaxis, or cannot safely receive adrenaline

The registry criteria, word for word

Show all 24 criteriaShow less

Who can take part

  • Patients who signed and dated informed consent form obtained prior to any study-specific examination
  • Female or male patients between 18 and 65 years of age at the time of signing the informed consent form
  • Positive result (≥ 3 mm) in a skin prick test performed with a positive control (histamine dihydrochloride 10 mg/mL) used in routine clinical practice, and negative result (< 2 mm) in a skin prick test performed with a negative control (glycerinated phenolated saline solution) used in routine clinical practice
  • Assumed compliance and ability of the patient to understand the patient's diary and to follow the instructions of the study staff
  • Patients suffering from rhinitis / rhinoconjunctivitis, with well-controlled mild-to-moderate asthma or without asthma, due to the exposure to any of the allergen sources under investigation, for at least 2 years in case of seasonal allergenic sources or for at least 1 year in case of perennial allergenic sources
  • Patients with a previous diagnosis of IgE-mediated allergy (type I) to any of the allergen sources under investigation verified by: a Retrospective Rhinoconjunctivitis Total Symptom Score (RRTSS) ≥ 1, (0-3 scale), according to Pfaar et al. (2014), during the period of highest exposure to the allergen source preceding the enrolment and, a positive skin prick test (mean wheal sdiameter ≥ 3 mm) when tested with a biologically standardized extract ued in routine clinical practice and, specific IgE (CAP (EAST) class ≥ 3 (i. e. value ≥ 3.50 kU/L)
  • In addition, for patients with a negative case history (“true non-allergic” patients) to any of the allergen extracts under investigation: • Non-atopic patients or patients sensitized to any allergen extract but those under investigation1 or any cross-reactive allergen source, verified by: a negative skin prick test (mean wheal diameter < 3d mm) to any of the allergen sources under investigation when tested with a biologically standardized extract prouct used in routine clinical practice and IgE (CAP (EAST) class < 1 (i. e. value < 0.35 kU/L) to the allergen source

Who cannot take part

  • Patients who are using drugs that may interfere with the SPTs (according to Bousquet J. 1992, Rüeff F. 2011 and Heinzerling et al. 2013)
  • Patients receiving allergen immunotherapy (AIT) or who received AIT in the past to any of the allergen extracts under investigation or to any cross-reactive allergen extract
  • Patients receiving treatment with beta-blockers
  • Completed or ongoing treatment with an anti-IgE-antibody (like Omalizumab) and/or checkpoint inhibitor
  • Skin disorders such as dermographism, atopic dermatitis, urticaria, cutaneous mastocytosis or tattoos at the test application area
  • Contraindication for adrenaline (for example, acute or chronic symptomatic coronary heart disease, severe hypertension, hyperthyroidism, glaucoma)
  • Patients with any severe psychiatric and psychological disorders, including impairment of cooperation (e. g., alcohol or drug abuse)
  • In addition, for patients with a negative case history (“true non-allergic” patients): • Patients sensitized to any allergen source with demonstrated cross-reactivity with the allergen sources under investigation
  • Patients with hypersensitivity to any of the excipients of the SPT-RX allergen extract solutions under investigation
  • Any severe generalised disease (liver, kidney, heart, metabolic disease) or autoimmune disease, immune-defect, including immunosuppression, immune-complex-induced immunopathy, or any infection or inflammation of the respiratory tract at the time of inclusion
  • Patients with any other contraindications for performing skin prick test
  • Risk of non-compliance by the patient with the study procedures
  • Relationship or dependence with the sponsor and/or investigator, legal incapacity, or patients who are jurisdictional or governmentally institutionalized
  • Subjects currently participating in another clinical trial
  • Only for asthmatic patients, severe, partly controlled or uncontrolled asthma according to the GINA guideline (Global Initiative for Asthma, 2025) or forced expiratory volume (FEV1) in one second ≤ 80 % of predicted normal value or known high degree of bronchial hyperreactivity
  • Patients at high risk of anaphylaxis according to their medical history
  • Pregnancy and/or breastfeeding

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 64 years old?

Where in Germany

Also in 1 other country, 6 sites

  • HNO Zentrum am KudammBerlin-Charlottenburg, GermanyNot yet recruiting
  • HNO-Praxis Dr. med. Udo SchäferDresden, GermanyNot yet recruiting
  • Praxis für HNO und Allergologie Dr. Yury YarinDresden, GermanyNot yet recruiting
  • HNO Praxis GöttingenGöttingen, GermanyNot yet recruiting

About the trial

What the trial wants to find out

The purpose of this clinical trial is to assess the diagnostic performance of SPT-RX solutions containing different allergen extracts administered by skin prick-test procedure, by means of the establishment of the sensitivity and specificity for each allergen extract.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).
Official title
International, multicenter, blinded phase III clinical trial to assess the diagnostic efficacy of the skin prick test from ROXALL (SPT-RX) with different allergen extract solutions for in vivo diagnosis of IgE mediated allergies
Plain-language title
Skin prick test with allergen extracts to diagnose allergies in adults with rhinitisGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 9 November 2026.
Fit questions
Built from 2025-524676-32-00, who can take part
Record updated
9 September 2026